A clinical trial comparing the effectiveness of pazopanib versus sunitinib in treating people with advanced kidney cancer.

Phase 1

• Conditions: ocally Advanced and/or Metastatic Renal Cell Carcinoma; MedDRA version: 21.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2008-002102-19-SE
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-30
• Last Update Posted: 7 June 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 927

Inclusion Criteria

Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 532
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 395

Exclusion Criteria

Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified